Patents Assigned to Kolon TissueGene, Inc.
-
Publication number: 20240115668Abstract: The present application discloses method of treating spinal cord injury, or a condition associated with or caused by spinal cord injury comprising regenerating nerve or attenuating degeneration of nerve at a site of nerve injury comprising administering at or an area near an injured nerve, a nerve regenerating or nerve degeneration attenuating amount of phosphatase and tensin homolog (PTEN) lipid phosphatase inhibiting peptide.Type: ApplicationFiled: December 6, 2021Publication date: April 11, 2024Applicant: KOLON TISSUEGENE, INC.Inventors: Moon Jong NOH, Kwangwook AHN
-
Publication number: 20230256055Abstract: A method for restoring a damaged or degenerating intervertebral disc, which includes administering a mixed cell composition containing mammalian connective tissue cells and mammalian cells expressing TGF-?1 into the intervertebral disc defect site.Type: ApplicationFiled: April 13, 2023Publication date: August 17, 2023Applicant: Kolon Tissuegene, Inc.Inventors: Moon Jong NOH, Huan T. Tran
-
Publication number: 20230256025Abstract: A method for preventing and treating back pain including discogenic back pain, which includes administering a mixed cell composition containing mammalian connective tissue cells and mammalian cells expressing TGF-?1 into the intervertebral disc defect site.Type: ApplicationFiled: April 13, 2023Publication date: August 17, 2023Applicant: KOLON TISSUEGENE, INC.Inventors: Moon Jong NOH, Huan T. Tran
-
Patent number: 11614441Abstract: The present invention provides a method for evaluating effectiveness of a cell therapeutic agent. When using TGF-? and/or TSP-1 expression level(s) in: (a) a first population of transformed mammalian cells with TGF-?; and (b) a second population of untransformed mammalian cells with the same gene, respectively, as a criterion for determining effectiveness of a cell therapeutic agent, and whether or not expression thereof, it is possible to definitely determine the therapeutic efficacy of each cell therapeutic agent prior to initiation of the treatment. In addition, since use of a cell therapeutic agent without therapeutic effects is avoided, undesired procedures and side effects may not be entailed.Type: GrantFiled: June 29, 2018Date of Patent: March 28, 2023Assignees: KOLON LIFE SCIENCE, INC., KOLON TISSUEGENE, INC.Inventors: Su Jeong Kim, Sang Eun Noh, Jun Ho Lee, Hyeon Youl Lee, Kyoung Baek Choi, Heon Sik Choi
-
Publication number: 20220193307Abstract: The present application is directed to a method of treating osteoarthritis, which includes obtaining a member of a transforming growth factor superfamily of proteins; obtaining a population of cultured mammalian cells that may contain vector encoding a gene, or a population of cultured connective tissue cells that do not contain any vector encoding a gene; and then transferring the protein and the connective tissue cells into an arthritic joint space of a mammalian host, such that the activity of the combination within the joint space results in regenerating connective tissue.Type: ApplicationFiled: March 30, 2020Publication date: June 23, 2022Applicant: Kolon Tissuegene, Inc.Inventors: Moon Jong Noh, Youngsuk Yi, Sun Uk Song, Dug Keun Lee, Kwan Hee Lee
-
Publication number: 20220160781Abstract: The subject invention is directed to a mixed cell composition to generate a therapeutic protein at a target site by providing a first population of mammalian cells transfected or transduced with a gene that is sought to be expressed, and a second population of mammalian cells that have not been transfected or transduced with the gene, wherein endogenously existing forms of the second population of mammalian cells are decreased at the target site, and wherein generation of the therapeutic protein by the first population of mammalian cells at the target site stimulates the second population cells to induce a therapeutic effect.Type: ApplicationFiled: March 30, 2020Publication date: May 26, 2022Applicant: Kolon Tissuegene, Inc.Inventors: Moon Jong Noh, Youngsuk Yi, Sun Uk Song, Kwan Hee Lee
-
Publication number: 20220160834Abstract: The present application discloses a method for preventing or retarding degeneration of intervertebral disc at an intervertebral disc defect site, which includes injecting a mammalian connective tissue cell into the intervertebral disc defect site.Type: ApplicationFiled: March 30, 2020Publication date: May 26, 2022Applicant: Kolon Tissuegene, Inc.Inventors: Moon Jong Noh, Hyun Bae, Sung Woo Kang, Kwan Hee Lee
-
Patent number: 11248211Abstract: The subject invention is directed to a composition comprising primed connective tissue cells and a pharmaceutically acceptable carrier thereof.Type: GrantFiled: November 25, 2009Date of Patent: February 15, 2022Assignee: KOLON TISSUEGENE, INC.Inventors: Moon Jong Noh, Youngsuk Yi, Kwan Hee Lee
-
Publication number: 20210177939Abstract: The present application discloses a method for preventing or retarding degeneration of intervertebral disc at an intervertebral disc defect site, which includes injecting a mammalian connective tissue cell into the intervertebral disc defect site.Type: ApplicationFiled: February 26, 2021Publication date: June 17, 2021Applicant: Kolon TissueGene, Inc.Inventors: Moon Jong NOH, Hyun BAE, Sung Woo KANG, Kwan Hee LEE
-
Publication number: 20210052662Abstract: The present application discloses a method for preventing or retarding degeneration of intervertebral disc at an intervertebral disc defect site, which includes injecting a mammalian connective tissue cell into the intervertebral disc defect site.Type: ApplicationFiled: November 9, 2020Publication date: February 25, 2021Applicant: Kolon TissueGene, Inc.Inventors: Moon Jong Noh, Hyun Bae, Sung Woo Kang, Kwan Hee Lee
-
Publication number: 20200270319Abstract: The present application discloses a method of growing or proliferating nerve cells by contacting the cells with phosphatase and tensin homolog (PTEN) lipid phosphatase inhibiting peptide.Type: ApplicationFiled: March 5, 2020Publication date: August 27, 2020Applicant: Kolon TissueGene, Inc.Inventors: Kwan Hee LEE, Moon Jong NOH, Kwangwook AHN
-
Patent number: 10584153Abstract: The present application discloses a method of growing or proliferating nerve cells by contacting the cells with phosphatase and tensin homolog (PTEN) lipid phosphatase inhibiting peptide.Type: GrantFiled: April 29, 2016Date of Patent: March 10, 2020Assignee: Kolon TissueGene, Inc.Inventors: Kwan Hee Lee, Moon Jong Noh, Kwangwook Ahn
-
Publication number: 20190224249Abstract: The present application discloses a method for preventing or retarding degeneration of intervertebral disc at an intervertebral disc defect site, which includes injecting a mammalian connective tissue cell into the intervertebral disc defect site.Type: ApplicationFiled: March 29, 2019Publication date: July 25, 2019Applicant: Kolon TissueGene, Inc.Inventors: Moon Jong Noh, Hyun Bae, Sung Woo Kang, Kwan Hee Lee
-
Publication number: 20190224248Abstract: The present application is directed to a method of treating osteoarthritis, which includes obtaining a member of a transforming growth factor superfamily of proteins; obtaining a population of cultured mammalian cells that may contain vector encoding a gene, or a population of cultured connective tissue cells that do not contain any vector encoding a gene; and then transferring the protein and the connective tissue cells into an arthritic joint space of a mammalian host, such that the activity of the combination within the joint space results in regenerating connective tissue.Type: ApplicationFiled: March 29, 2019Publication date: July 25, 2019Applicant: Kolon TissueGene, Inc.Inventors: Moon Jong Noh, Youngsuk Yi, Sun Uk Song, Dug Keun Lee, Kwan Hee Lee